1-(1-benzyl-2,5-dimethyl-1H-pyrrol-3-yl)-2-chloroethan-1-one | 610274-26-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(1-benzyl-2,5-dimethyl-1H-pyrrol-3-yl)-2-chloroethan-1-one
• 英文别名: 1-(1-benzyl-2,5-dimethyl-1H-pyrrol-3-yl)-2-chloroethanone；1-(1-benzyl-2,5-dimethylpyrrol-3-yl)-2-chloroethanone
• CAS: 610274-26-5
• 化学式: C₁₅H₁₆ClNO
• mdl: MFCD04629634
• 分子量: 261.751
• InChiKey: OXABFSIGNVGMCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.266
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-(1-benzyl-2,5-dimethyl-1H-pyrrol-3-yl)-2-chloroethan-1-one 在 caesium carbonate 、 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 96.0h， 生成 1-(1-(1-benzyl-2,5-dimethyl-1H-pyrrol-3-yl)-1-oxopropan-2-yl)-5-bromopyridin-2(1H)-one
  参考文献：
  名称：

  [EN] PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF
  [FR] COMPOSÉS À BASE DE PYRIDINONE ET DE PYRIDAZINONE ET UTILISATIONS MÉDICALES ASSOCIÉES

  摘要：

  本文提供的各种示例涉及到以下公式的化合物A-L1-Het1-L2-Cy1或其药用可接受的盐、多型体、前药、溶剂合物或包合物，其中：A为环烷基、芳基、芳基烷基或杂环烷基；Het1为含有至少两个杂原子的杂环烷基；Cy1为杂环烷基；L1为键、烷基、烯基或炔基连接物；L2为酰基或烷基连接物；A和Cy1不同。这些化合物在治疗纤维化疾病、异常血管渗漏和病理性血管生成方面具有用途。

  公开号：

  WO2019173790A1

文献信息

• A sphingosine 1-phosphate receptor 2 selective allosteric agonist
  作者：Hideo Satsu、Marie-Therese Schaeffer、Miguel Guerrero、Adrian Saldana、Christina Eberhart、Peter Hodder、Charmagne Cayanan、Stephan Schürer、Barun Bhhatarai、Ed Roberts、Hugh Rosen、Steven J. Brown

  DOI：10.1016/j.bmc.2013.06.012

  日期：2013.9

  Molecular probe tool compounds for the Sphingosine 1-phosphate receptor 2 (S1PR2) are important for investigating the multiple biological processes in which the S1PR2 receptor has been implicated. Amongst these are NF-kappa B-mediated tumor cell survival and fibroblast chemotaxis to fibronectin. Here we report our efforts to identify selective chemical probes for S1PR2 and their characterization. We employed high throughput screening to identify two compounds which activate the S1PR2 receptor. SAR optimization led to compounds with high nanomolar potency. These compounds, XAX-162 and CYM-5520, are highly selective and do not activate other SIP receptors. Binding of CYM-5520 is not competitive with the antagonist JTE-013. Mutation of receptor residues responsible for binding to the zwitterionic headgroup of sphingosine 1-phosphate (S1P) abolishes S1P activation of the receptor, but not activation by CYM-5520. Competitive binding experiments with radiolabeled S1P demonstrate that CYM-5520 is an allosteric agonist and does not displace the native ligand. Computational modeling suggests that CYM-5520 binds lower in the orthosteric binding pocket, and that co-binding with SIP is energetically well tolerated. In summary, we have identified an allosteric S1PR2 selective agonist compound. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
• PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF
  申请人：Cook, Timothy, H.

  公开号：EP3762377A1

  公开（公告）日：2021-01-13
• PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF
  申请人：Hla Timothy

  公开号：US20200407339A1

  公开（公告）日：2020-12-31

  The various examples presented herein are directed to compounds of the formula A-L 1 -Het 1 -L 2 -Cy 1 or a pharmaceutical acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: A is cycloalkyl, aryl, arylalkyl or heterocyclyl; Het 1 is heterocyclyl containing at least two heteroatoms; Cy 1 is a heterocyclyl; L 1 is a bond, alkyl, alkenyl or alkynyl linker; L 2 is an acyl or alkyl linker; and A and Cy 1 are different. The compounds are useful in the treatment of fibrotic diseases, abnormal vascular leak and pathological angiogenesis.
• [EN] PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF<br/>[FR] COMPOSÉS À BASE DE PYRIDINONE ET DE PYRIDAZINONE ET UTILISATIONS MÉDICALES ASSOCIÉES
  申请人：HLA TIMOTHY

  公开号：WO2019173790A1

  公开（公告）日：2019-09-12

  The various examples presented herein are directed to compounds of the formula A-L1-Het1-L2-Cy1 or a pharmaceutical acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: A is cycloalkyl, aryl, arylalkyl or heterocyclyl; Het1 is heterocyclyl containing at least two heteroatoms; Cy1 is a heterocyclyl; L1 is a bond, alkyl, alkenyl or alkynyl linker; L2 is an acyl or alkyl linker; and A and Cy1 are different. The compounds are useful in the treatment of fibrotic diseases, abnormal vascular leak and pathological angiogenesis.

  本文提供的各种示例涉及到以下公式的化合物A-L1-Het1-L2-Cy1或其药用可接受的盐、多型体、前药、溶剂合物或包合物，其中：A为环烷基、芳基、芳基烷基或杂环烷基；Het1为含有至少两个杂原子的杂环烷基；Cy1为杂环烷基；L1为键、烷基、烯基或炔基连接物；L2为酰基或烷基连接物；A和Cy1不同。这些化合物在治疗纤维化疾病、异常血管渗漏和病理性血管生成方面具有用途。